EUCTR2008-003064-19-DE进行中（未招募）1 期
Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative Mammacarcinoma - NeoTEC-Studie
niversität Leipzig0 个研究点开始时间: 2008年10月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Women with histologically verified mamma carcinoma (assessment of estrogen and progesterone receptors, grading, negative HER-2/neu status)
- •All receptor-negative mamma carcinoma starting from cT1c, all receptor-positive mamma carcinoma starting from cT3, cT4 includes inflammatory mamma carcinoma
- •In case of cT2 and receptor-positivity, N+ is required and can also be detected with sentinel node biopsy
- •In case of cT1c and receptor-positivity, a positive lymph node must be verified with sentinel node biopsy (pNsn+)
- •Clinically and with an imaging technology (sonography or mammography) measurable primary tumor
- •Sufficient bone marrow reserve: number of neutrophils >= 1,5 x 1000000000/L, number of thrombocytes >= 100 x 1000000000/L, hemoglobin >= 6,2 mmol/L
- •Sufficient liver and renal function: bilirubin <=1 x upper limit of quantification (ULQ), ASAT (SGOT) and ALAT (SGPT) < 1,5 x ULQ, alcalic phosphatase < 1,5 x ULQ, Creatinine < 1 x ULQ (if creatinine > ULQ creatinine clearance must be > 60 mL/minute)
- •Age-appropriate cardiologically normal findings as documented by ECG and LVEF (echocardiographical) assessments before beginning the therapy
- •ECOG-performance-status of 0-2
- •Age >=18 years
- •Written informed consent of the patient including compliance of the patient regarding the therapy and the follow-up must be available before enrolment and documented according to the local regulations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •Pregnant or nursing women. Positive pregnancy test (urine or serum) within 7 days before registration
- •Previous surgical, cytostatic or hormonal therapy (with exception of hormone substitution or contraception), no previous immune or radiation therapy
- •Women with child bearing potency (menopause according to hormone status) without effective non-hormonal contraception (intra-uterine devices – spirals, condoms in combination with additional contraceptic measures, vasectomised partner) during the participation in the study and 6 months after the end of study therapy.
- •Bilateral localisation of tumors
- •Evidence of distant metastases after complete staging with chest X-ray, upper abdomen sonography, and/or CT and bone scintigraphy
- •Pre-existing motor or sensor neurotoxicity > grade 2 (according to NCl criteria)
- •Pre-existing cardiac disease not permitting the participation in this study (e.g. severe heart insufficiency or unstable angina pectoris, cardiac infarction within one year before study entry, uncontrolled hypertension, therapy resistant arrhythmia
- •Significant neurological or psychiatric disease in the anamnesis (including psychotic disorders, dementia or seizures) compromising the understanding of the trial and consent to the trial.
- •Drug abuse
- •Active infection
- •Florid ulcus, unstable diabetes mellitus
- •Previously diagnosed tumor with exception of basalioma or in situ carcinoma of the cervix or other cancers having been treated curatively and having been followed by a disease-free interval of < 10 years.
- •Chronic treatment with corticosteroids if not started > 6 months before study entry and at low doses (< 20 mg Methylprednisolone or equivalents)
- •Clear contraindication for the application of corticosteroids
- •Contraindication of the planned therapy:
- •- hypersensitivity to one of the trial drugs (Docetaxel, Cyclophosphamide and Epirubicine)
- •- extensive inflammatory condition of oral or gastrointestinal mucous membrane
- •Lack of compliance
- •Concomitant participation in other clinical trials
研究者
相似试验
已完成
2 期
Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative MammacarcinomaMedDRA - 10006187: Primary mamma carcinomaC50Malignant neoplasm of breastDRKS00000162niversität Leipzig152
招募中
2 期
A study of neoadjuvant PEMbrolizumab before radical PROstatectomy (PEM-PRO) in patients affected by high-risk prostate cancer2024-514580-26-00Ospedale San Raffaele S.r.l.59
进行中（未招募）
1 期
A phase II, single arm study investigating neoadjuvant plus adjuvant treatment with Cemiplimab in high risk, surgically resectable, stage III Cutaneaous Squamous Cell Carcinomahigh risk, surgically resectable, stage III Cutaneous Squamous Cell CarcinomaMedDRA version: 21.1Level: PTClassification code 10041834Term: Squamous cell carcinoma of skinSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001469-34-ITFONDAZIONE MELANOMA ONLUS25
进行中（未招募）
不适用
Phase IIa study to investigate the efficacy of NOX-H94 in the treatment of anemia in patients with cancer.anemia of chronic disease in patients with cancerMedDRA version: 16.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864MedDRA version: 16.0Level: LLTClassification code 10054310Term: Anemia of chronic diseaseSystem Organ Class: 100000004851EUCTR2012-001525-27-ATOXXON Pharma AG48
进行中（未招募）
1 期
Phase IIa study to investigate the efficacy of NOX-H94 in the treatment of anemia in patients with cancer.EUCTR2012-001525-27-BGOXXON Pharma AG48